文献速递脊柱关节炎

古塞奇尤单抗治疗银屑病关节炎的比较有效性:系统文献综述与网状Meta分析

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

结果显示古塞奇尤单抗100 mg每8周在ACR 20/50/70应答上与IL-17A抑制剂及皮下TNF抑制剂相当,PASI 75/90优于多数其它药物,安全性比较结论不确定。

要点

  • 古塞奇尤单抗100 mg每8周关节疗效与IL-17A抑制剂及皮下TNF抑制剂相当
  • PASI 75/90应答古塞奇尤单抗优于多数其它靶向药,PASI 100与其它活性药相当
  • 不良事件与严重不良事件排名较高但比较结论不确定

核心结论

  • 在网状Meta分析中,古塞奇尤单抗显示出与IL-17A抑制剂和皮下TNF抑制剂相当的关节疗效,同时相对许多其它治疗提供更好的PASI应答。

主要发现

  • ACR 20应答方面,古塞奇尤单抗100 mg每8周与IL-17A抑制剂及皮下TNF抑制剂相当,ACR 50和ACR 70结果类似。
  • vdH-S评分方面,古塞奇尤单抗每8周除静脉TNF治疗外与其它药物相当。
  • PASI 75和PASI 90应答提示古塞奇尤单抗每8周优于多数其它药物,PASI 100与其它活性药物相当。
  • 不良事件和严重不良事件方面古塞奇尤单抗每8周排名较高,但比较结论不确定。
  • 古塞奇尤单抗100 mg每4周在所有结局上观察到类似结果。

临床怎么用

  • 对于银屑病关节炎患者,古塞奇尤单抗可作为兼顾关节与皮肤疗效的靶向治疗选择之一,其关节疗效与IL-17A及皮下TNF抑制剂相当。

局限性

  • 不良事件与严重不良事件的比较结论不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 & -2) but has not been evaluated vs other targeted therapies for PsA. The objective was to compare guselkumab to targeted therapies for PsA for safety and joint and skin efficacy through network meta-analysis (NMA). METHODS: A systematic literature review was conducted in January 2020 to identify randomized controlled trials. Bayesian NMAs were performed to compare treatments on American College of Rheumatology (ACR) 20/50/70 response, mean change from baseline in van der Heijde-Sharp (vdH-S) score, Psoriasis Area Severity Index (PASI) 75/90/100 response, adverse events (AEs) and serious adverse events (SAEs). RESULTS: Twenty-six phase 3 studies evaluating 13 targeted therapies for PsA were included. For ACR 20 response, guselkumab 100 mg every 8 weeks (Q8W) was comparable to IL-17A inhibitors and subcutaneous tumor necrosis factor (TNF) inhibitors. Similar findings were observed for ACR 50 and 70. For vdH-S score, guselkumab Q8W was comparable to other agents except intravenous TNF therapies. Results for PASI 75 and PASI 90 response suggested guselkumab Q8W was better than most other agents. For PASI 100, guselkumab Q8W was comparable to other active agents. For AEs and SAEs, guselkumab Q8W ranked highly but comparative conclusions were uncertain. Similar results were observed for all outcomes for guselkumab 100 mg every four weeks. CONCLUSIONS: In this NMA, guselkumab demonstrated favorable arthritis efficacy comparable to IL-17A and subcutaneous TNF inhibitors while offering better PASI response relative to many other treatments.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021. PMID: 33844022. doi:10.1093/rheumatology/keab119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。